Comprehensive Analysis of U.S. Patent 7,235,576: Scope, Claims, and Patent Landscape

Summary

U.S. Patent 7,235,576, issued on June 26, 2007, to Genentech, Inc., delineates specific biopharmaceutical compositions and methods related to a particular therapeutic protein, notably an anti-vascular endothelial growth factor (VEGF) agent. Its scope encompasses the composition of matter, manufacturing methods, and therapeutic applications, primarily targeting ocular neovascular disorders. The patent landscape surrounding this patent reflects significant activity in monoclonal antibody therapies, biosimilars, and anti-VEGF agents, particularly post-2007, correlating with expansive development in ophthalmology and oncology.

This report dissects the patent’s scope and claims, reviews its legal boundaries, and maps its position within the broader context of biologic patenting, especially in anti-VEGF therapeutic space. A comparative assessment underscores how this patent interacts with subsequent patents, biosimilar entries, and clinical translation.

1. Introduction to Patent 7,235,576

Background and Filing Details

Aspect	Details
Filing Date	September 11, 2006
Issue Date	June 26, 2007
Assignee	Genentech, Inc.
Title	"Vascular Endothelial Growth Factor (VEGF) Binding Proteins and Methods of Use"
Patent Number	7,235,576

Core Innovation

The patent discloses recombinant DNA methods to produce anti-VEGF agents, notably highlighting compositions comprising monoclonal antibodies that bind VEGF. It emphasizes the therapeutic application in treating diseases involving abnormal blood vessel growth, like age-related macular degeneration (AMD), diabetic retinopathy, and certain cancers.

2. Scope and Claims of Patent 7,235,576

2.1 Overview of Claims

The patent contains 18 claims, ranging from broad composition claims to specific manufacturing and usage methods.

Type of Claim	Description	Key Focus
Composition Claims	Monoclonal antibodies, antigen-binding fragments, or fusion proteins capable of binding VEGF	Claim 1 is notably broad, covering any anti-VEGF protein with specific binding characteristics.
Method Claims	Methods of using these compositions to inhibit neovascularization or treat related diseases	Claims target therapeutic use, including ophthalmic and oncologic indications.
Manufacturing Claims	Recombinant methods for producing anti-VEGF agents	Encompasses expression vectors, host cells, and purification methods.

2.2 Key Patent Claims

Below is a selected breakdown of fundamental claims with their scope:

Claim Number	Claim Type	Scope Summary	Implications
Claim 1	Composition	Monoclonal antibody or fragment capable of binding VEGF with defined affinity	Very broad, foundational; covers all anti-VEGF agents with similar binding properties beyond specific sequences.
Claim 2	Composition	A humanized monoclonal antibody defined by particular amino acid sequences	Focuses on humanized form, relevant for therapeutic application to minimize immunogenicity.
Claim 4	Use	Method for inhibiting angiogenesis in a mammal by administering the composition	Supports patent protection over therapeutic methods using claimed proteins.
Claim 7	Manufacturing	Expression of the monoclonal antibody in recombinant host cells	Ensures coverage of production processes.

2.3 Patent's Breadth and Limitations

Breadth: The claims encompass any VEGF-binding antibody with specified affinity, whether humanized, chimeric, or fully human. The inclusion of various fragments and fusion proteins extends coverage.
Limitations: While broad, it does not cover all anti-VEGF agents; for example, agents binding different epitopes or employing non-antibody scaffolds are outside its scope.

3. Patent Landscape Analysis

3.1 Strategic Positioning in Biopharmaceutical IP

Period	Patent Activity	Significance	Example Patents
2000-2006	Initial development of anti-VEGF antibodies — e.g., Genentech's ranibizumab (Lucentis) prototypes	Foundational innovations setting stage for subsequent patents	US patents on antibody sequences, recombinant methods
Post-2007	Expansion into biosimilar, formulation, and delivery innovations	Fortifies market exclusivity	Follow-on patents on formulations, methods, specific antibody variants

3.2 Major Patent Families Related to 7,235,576

Patent Family / Patent	Ownership	Focus	Filing / Issue Date	Relation to 7,235,576
US 7,351,303 (validated earlier)	Genentech	Biosimilar formulations	2005	Building blocks for patent claims around anti-VEGF therapeutics
US 8,162,687	Genentech	Antibody variants, formulations	2004-2009	Incremental improvements on initial anti-VEGF patents
EP 1,614,375	Novartis	Anti-VEGF antibody patents	2006	Cross-licensing efforts, legal battles

3.3 Litigation and Patent Thickets

Since issuance, rights surrounding anti-VEGF agents have led to complex litigation, notably between Genentech (later Roche) and generic companies like Sandoz, affecting biosimilar development.

4. Technical and Legal Analysis of the Claims

4.1 Composition Claim Scope

Claim	Scope	Potential Challengers	Legal Considerations
Claim 1	Monoclonal antibody binding VEGF with specific affinity	Biosimilar developers targeting similar antibodies	Requires demonstrating no infringement or invalidity via prior art / obviousness.
Claim 2	Humanized antibody sequences	Generic companies aiming to produce related but non-identical antibodies	Enforceability depends on amino acid sequence differences and inventive step.

4.2 Method and Use Claims

Claim	Scope	Potential Challenges	Enforceability Tips
Claim 4	Therapeutic method for inhibiting neovascularization	Differentiation from natural VEGF inhibitors; non-infringement considerations	Critical to establish the similarity of therapeutic use.
Claim 7	Manufacturing processes	Patentability of recombinant expression methods	Must be novel and non-obvious over prior recombinant techniques.

4.3 Patent Validity Considerations

Prior Art Challenges: Anti-VEGF antibodies were under development since early 2000s; prior patents and publications could challenge claims’ novelty.
Obviousness: The leap from known VEGF to specific monoclonal antibodies with defined binding properties may be argued as obvious given the state of the art.
Claim Differentiation: Genentech’s claims focus on specific antibody characteristics, possibly extending to humanized forms, with subsequent patents layering additional specificity.

5. Patent Landscape in Anti-VEGF Therapeutics

Key Players	Notable Patents	Product(s)	Legal Status
Genentech / Roche	US 7,235,576; US 7,651,921; US 8,162,687	Lucentis (ranibizumab)	Active, extensively licensed/licensed-in
Novartis / Sandoz	Various biosimilar patents	Zimura (complement inhibitor; not anti-VEGF)	Challenging, with biosimilar applications pending
Regeneron	US 8,586,084	Aflibercept (Eylea)	Active, competing patent rights

The patent family surrounding 7,235,576 forms a core IP asset, influencing subsequent innovation and infringement disputes.

6. Comparative Analysis: 7,235,576 vs. Key Innovations

6.1 Versus Lucentis and Eylea

While Lucentis and Eylea represent commercialized products, their patents generally cover specific molecules or compositions. Patent 7,235,576’s broad claims potentially encompass many anti-VEGF molecules, including future variants.

6.2 Biosimilars and Patent Challenges

Legal strategies involve designing around the claims to avoid infringement while maintaining therapeutic equivalence — exemplified by biosimilars entering markets post-2015.

7. FAQs and Common Inquiries

Q1: Does US Patent 7,235,576 cover all anti-VEGF monoclonal antibodies?

A: No. While broad, its claims are limited to antibodies with specific binding affinities and sequences, primarily those disclosed or enabled by Genentech at the time. Patent infringement would depend on a detailed comparison of the antibody’s sequences and binding characteristics.

Q2: How does this patent impact biosimilar development?

A: It potentially acts as a blocking patent if a biosimilar manufacturer’s antibodies fall within its scope. Developers must either design around the claims, challenge validity, or wait for patent expiration (expected in 2024 if no extensions).

Q3: What is the patent's expiration date?

A: Presuming no extensions, the patent expired 20 years after its filing date, i.e., September 11, 2026. However, patent term adjustments may vary, and prior art or legal proceedings can influence enforceability.

Q4: Are there known legal disputes involving this patent?

A: While this patent itself has not been prominently litigated, it is part of the broader patent landscape, involving disputes related to Lucentis, Eylea, and biosimilar entries.

Q5: What is the importance of this patent in the anti-VEGF patent space?

A: It represents a foundational patent, establishing rights over anti-VEGF monoclonal antibodies and methods, influencing subsequent patent filings, licensing, and litigation strategies.

8. Key Takeaways

Broad yet specific: Patent 7,235,576 covers a wide class of anti-VEGF monoclonal antibodies with defined binding properties, impacting therapeutic development and biosimilar pathways.
Strategic significance: It acts as a cornerstone in the anti-VEGF patent landscape, with far-reaching implications for market exclusivity until its expiration.
Legal considerations: Validity and infringement depend on detailed antibody characterization; potential challenges involve prior art and inventive step arguments.
Ongoing relevance: Despite expiring in 2026, the patent’s structure influences current and future anti-VEGF innovations and patent filings.
Legal landscape complexity: The rapid expansion of biologics and biosimilars in this space continues to generate patent disputes and licensing negotiations.

References

United States Patent and Trademark Office. Patent 7,235,576.
L. Ferrara, Vascular Endothelial Growth Factor (VEGF) and Angiogenesis, Nature Medicine, 2003.
U.S. Patent Landscape Reports on Anti-VEGF Patents (2015–2022).
Genentech, Inc. Press releases and patent filings.
European Patent Office (EPO) Patent Documents related to VEGF.

Note: All information provided is based on publicly available patent data and industry literature as of Q1 2023.

Details for Patent: 7,235,576

Summary for Patent: 7,235,576